Increased pollen concentrations are correlated with higher rates of COVID-19. Hot on the heels of record-breaking European pollen counts, this comes as bad news for a continent struggling with the ongoing health crisis. The large-scale study, conducted by an international team headed by researchers in Germany, suggested people protect themselves by keeping an eye on pollen forecasts and wearing particle filtering masks this spring.
A Belgian invention is revolutionizing cancer diagnostics for dogs by making it possible to screen for two common canine cancers with a simple, low-cost blood test. The innovation was developed by the Belgian subsidiary of Volition, a multinational company listed on the New York stock exchange. The company is also developing human blood tests for use in oncology as well as a number of other diseases including COVID-19.
Heusden-Zolder, Belgium, 2 March 2021 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing prescription drugs for age-related diseases, announces it has completed a EUR 3.2 million Series A round. The funding is being used to advance the development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
V-Bio Ventures recently announced their second fund, with the first closing already totaling 78 million euros [final close at 110 million euros - Ed.]. As a VC fund with a focus on early-stage life sciences companies, V-Bio will be using Fund 2 to continue supporting European start-ups working on effective healthcare or sustainable agriculture solutions. In this interview, co-founders Christina Takke and Willem Broekaert, along with new Managing Partner Shelley Margetson, share some success stories from V-Bio’s first five years and how they plan to create value for both investors and society in the future.
Brussels, Belgium, 24 February 2021 – Newton Biocapital I (“Newton Biocapital”), a life sciences investment fund active in Europe and Japan focused on chronic diseases, has announced investment in DeuterOncology. Newton Biocapital’s second investment in Flanders, DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies.
Ghent, Belgium, 23 February 2021 - The Ghent company Biogazelle and the medical laboratory Labo Nuytinck (Ghent, Evergem), together with several Flemish companies, have developed a PCR platform with which thousands of saliva samples can be tested daily for the COVID-19 virus. The saliva test costs a third of a classic test.
Micro-chip based µPAC™ LC columns – key component in Vienna IMP study measuring the proteome at picogram level
Ghent, Belgium, 15 February 2021 - PharmaFluidics NV, innovative life sciences instruments player, is excited to announce that researchers of Karl Mechtler’s Group at the Research Institute for Molecular Pathology in Vienna have integrated its ultra-sensitive second generation µPAC™ micro-Chip technology as a key enabler in their advanced Single Cell Proteomics workflow.
Increased pollen concentrations are correlated with higher rates of COVID-19. Hot on the heels of record-breaking European pollen counts, this comes as bad news for a continent struggling with the ongoing health crisis. The large-scale study, conducted by an international team headed by researchers in Germany, suggested people protect themselves by keeping an eye on pollen forecasts and wearing particle filtering masks this spring.
A Belgian invention is revolutionizing cancer diagnostics for dogs by making it possible to screen for two common canine cancers with a simple, low-cost blood test. The innovation was developed by the Belgian subsidiary of Volition, a multinational company listed on the New York stock exchange. The company is also developing human blood tests for use in oncology as well as a number of other diseases including COVID-19.
Heusden-Zolder, Belgium, 2 March 2021 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing prescription drugs for age-related diseases, announces it has completed a EUR 3.2 million Series A round. The funding is being used to advance the development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
V-Bio Ventures recently announced their second fund, with the first closing already totaling 78 million euros [final close at 110 million euros - Ed.]. As a VC fund with a focus on early-stage life sciences companies, V-Bio will be using Fund 2 to continue supporting European start-ups working on effective healthcare or sustainable agriculture solutions. In this interview, co-founders Christina Takke and Willem Broekaert, along with new Managing Partner Shelley Margetson, share some success stories from V-Bio’s first five years and how they plan to create value for both investors and society in the future.
Brussels, Belgium, 24 February 2021 – Newton Biocapital I (“Newton Biocapital”), a life sciences investment fund active in Europe and Japan focused on chronic diseases, has announced investment in DeuterOncology. Newton Biocapital’s second investment in Flanders, DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies.
Ghent, Belgium, 23 February 2021 - The Ghent company Biogazelle and the medical laboratory Labo Nuytinck (Ghent, Evergem), together with several Flemish companies, have developed a PCR platform with which thousands of saliva samples can be tested daily for the COVID-19 virus. The saliva test costs a third of a classic test.
Micro-chip based µPAC™ LC columns – key component in Vienna IMP study measuring the proteome at picogram level
Ghent, Belgium, 15 February 2021 - PharmaFluidics NV, innovative life sciences instruments player, is excited to announce that researchers of Karl Mechtler’s Group at the Research Institute for Molecular Pathology in Vienna have integrated its ultra-sensitive second generation µPAC™ micro-Chip technology as a key enabler in their advanced Single Cell Proteomics workflow.